Identification of potent, selective protein kinase C inhibitors based on a phorbol skeleton

Chemistry - An Asian Journal

Volumn 1, Issue 3, 2006, Pages 314-321

  Yamatsugu, Kenzo ^a   Motoki, Rie ^a   Kanai, Motomu ^a   Shibasaki, Masakatsu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Enzymes; Fluoroalkyls; Inhibitors; Phorbol esters; Protein kinase C

Indexed keywords

ADENOSINE TRIPHOSPHATE; ENZYME INHIBITOR; PHORBOL ESTER; PROTEIN KINASE C;

ANIMAL; ARTICLE; BINDING SITE; CHEMICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; IC 50; KINETICS; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; PROTEIN MOTIF;

ADENOSINE TRIPHOSPHATE; AMINO ACID MOTIFS; ANIMALS; BINDING SITES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; PHORBOL ESTERS; PROTEIN BINDING; PROTEIN KINASE C;

EID: 33749180779     PISSN: 18614728     EISSN: 1861471X     Source Type: Journal    
DOI: 10.1002/asia.200600185     Document Type: Article

References (52)

1. G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, Science 2002, 298, 1912.
2. a) Y. Nishizuka, FASEB J. 1995, 9, 484;
3. b) A. Toker, Front. Biosci. 1998, 3, D1134;
4. c) Protein Kinase C: Current Concepts and Future Perspectives (Eds.: D. S. Lester, R. M. Epand), Ellis Horwood, Chichester, 1992;
5. d) A. C. Newton, Curr. Opin. Cell Biol. 1997, 9, 161.
6. For a review of protein kinase inhibitors, see: A. J. Bridges, Chem. Rev. 2001, 101, 2541.
7. For selectivity evaluation of protein kinase inhibitors, see: a) S. P. Davies, H. Reddy, M. Caivano, P. Cohen, Biochem. J. 2000, 351, 95;
8. b) L. Saravia, P. Fresco, E. Pinto, J. Goncalves, J. Enzyme Inhib. Med. Chem. 2003, 18, 475.
9. 50 = 2.5 nM), but does not exhibit inhibitory activity against PKCδ, ε, and ζ.
10. For C1-domain-binding artificial DAG analogues (agonists), see: a) V. E. Marquez, K. Nacro, S. Benzaria, J. Lee, R. Sharma, K. Teng, G. W. A. Milne, B. Bienfait, S. Wang, N. E. Lewin, P. M. Blumberg, Pharmacol. Ther. 1999, 82, 251;
11. b) V. E. Marquez, P. M. Blumberg, Acc. Chem. Res. 2003, 36, 434;
12. c) J. Lee, J. Kang, K. Han, Y. Kim, S. Y. Kim, H. Youn, I. Mook-Jung, H. Kim, J. H. L. Han, H. J. Ha, Y. H. Kim, V. E. Marquez, N. E. Lewin, L. V. Pearce, D. J. Lundberg, P. M. Blumberg, J. Med. Chem. 2006, 49, 2028;
13. d) Y. Baba, Y. Ogoshi, G. Hirai, T. Yanagisawa, K. Nagamatsu, S. Mayumi, Y. Hashimoto, M. Sodeoka, Bioorg. Med. Chem. Lett. 2004, 14, 2963;
14. e) Y. Baba, S. Mayumi, G. Hirai, H. Kawasaki, Y. Ogoshi, T. Yanagisawa, Y. Hashimoto, M. Sodeoka, Bioorg. Med. Chem. Lett. 2004, 14, 2969.
15. N. C. Mishra, R. D. Estensen, M. M. Abdelmonem, J. Chromatography 1986, 369, 435.
16. a) U. Kikkawa, Y. Takai, Y. Tanaku, R. Miyake, Y. Nishizuka, J. Biol. Chem. 1983, 258, 11442. For reviews, see:
17. b) M. G. Kazanietz, M. J. Caloca, P. Eroles, T. Fujii, M. L. Garcia-Bermejo, M. Reilly, H. Wang, Biochem. Pharmacol. 2000, 60, 1417;
18. c) Y. Kishi, R. R. Rando, Acc. Chem. Res. 1998, 31, 163;
19. d) P. A. Wender, K. F. Kochler, N. A. Sharkey, M. L. Dell'Aquila, P. M. Blumberg, Proc. Natl. Acad. Sci. USA 1986, 83, 4214.
20. G. Zhnng, M. G. Kazanietz, P. M. Blumberg, J. H. Hurley, Cell 1995, 81, 917.
21. a) S. Wang, M. G. Kazanietz, P. M. Blumberg, V. E. Marquez, G. W. A. Milane, J. Med. Chem. 1996, 39, 2541;
22. b) J. Hritz, J. Ulicny, A. Laaksonen, D. Jancura, P. Miskovsky, J. Med. Chem. 2004, 47, 6547.
23. A. C. Newton, Chem. Rev. 2001, 101, 2353.
24. For inhibitors based on the phorbol ester skeleton, see: a) R. Wada, Y. Suto, M. Kanai, M. Shihasaki, J. Am. Chem. Soc. 2002, 124, 10658;
25. b) M. Sodeoka, M. A. Arai, K. Adachi, K. Uotsu, M. Shibasaki, J. Am. Chem. Soc. 1998, 120, 457;
26. c) T. M. Bertolini, J. Giorgione, D. F. Harvey, A. C. Newton. J. Org. Chem. 2003, 68, 5028;
27. d) P. A. Wender, T. A. Kirshberg, P. D. Williams, H. M. M. Bastiaans, K. Irie, Org. Lett. 1999, 1, 1009;
28. e) M. Tanaka, K. Irie, Y. Nakagawa, Y. Nakamura, H. Ohigashi, P. A. Wender, Bioorg. Med. Chem. Lett. 2001, 11, 719.
29. The calculated logP values of 3 and 4 are 2.49 and 2.18, respectively, which support our assumption.
30. There may also be affinitive interactions between the perfluoroalkyl group and PKC. For a review of the effects of fluorine substituents on biological activity, see: a) B. E. Smart, J. Fluorine Chem. 2001, 109, 3. For recent reports of interesting effects of fluoroalkyl substituents on biological activity and molecular structure, see:
31. b) S. Ortial, G. Durand, B. Poeggeler, A. Polidori, M. A. Pappolla, J. Böker, R. Hardeland, B. Pucci, J. Med. Chem. 2006, 49, 2812;
32. c) K. Monde, N. Miura, M. Hashimoto, T. Taniguchi, T. Inabe. J. Am. Chem. Soc. 2006, 128, 6000;
33. d) C. Jäckel, M. Salwiczek, B. Koksch, Angew. Chew. 2006, 118, 4305;
34. Angew. Chem. Int. Ed. 2006, 45, 4198.
35. 50 value of 6 than expected from its modest binding affinity is attributable to the partial agonistic character of 6. Even in the presence of a high concentration of 6, the PKC activity did not reach zero; see Supporting Information.
36. H. Hidaka, M. Inagaki, S. Kawamoto, Y. Sasaki, Biochemistry 1984, 23, 5036.
37. J. M. Herbert, J. M. Augereau, J. Gleyc and J. P. Maffrand, Biochem. Biophys. Res. Commun. 1990, 172, 993.
38. For detailed synthetic procedures and spectroscopic data of 8, see Supporting Information.
39. V. C. R. McLoughlin, J. Thrower, Tetrahedron 1969, 25, 5921.
40. Fluoroalkyl groups can significantly increase the membrane-binding ability. For example, see: G. Gerebtzoff, X. Li-Blatter, H. Fischer, A. Frentzel, A. Seelig, ChemBioChem 2004, 5, 676.
41. a) M. Sodeoka, K. Uotsu, M. Shibasaki, Tetrahedron Lett. 1995, 36, 8795;
42. b) K. Uotsu, M. Sodeoka, M. Shibasaki, Bio. Med. Chem. 1998, 6, 1117.
43. T. Okada, Analyst 1993, 118, 959.
44. A. F. G. Quest, J. Bloomenthal, E. S. G. Bardes, R. M. Bell, J. Biol. Chem. 1992, 267, 10193.
45. The same mechanism might be involved in the previous inhibitor 3.
46. Preliminary studies indicated that 8 has no significant cancer cell (K562) growth inhibitory activity.
47. A. E. J. Nooy, A. C. Besemer, H. Bekkum, Synthesis 1996, 1153.
48. T. Kametani, H. Sekine, T. Honda, Chem. Pharm. Bull. 1982, 30, 4545.
49. Y. Tanaka, R. Miyake, U. Kikkawa, Y. Nishizuka, J. Biochem. 1986, 99, 257.
50. Y. A. Hannun, C. R. Loomies, R. M. Bell, J. Biol. Chem. 1985, 260, 10039.
51. H. Nakanishi, J. H. Exton. J. Biol. Chem. 1992, 267, 16347.
52. J. D. Scott, E. H. Fischer, J. G. Demaille, E. D. Krebs, Proc. Natl. Acad. Sci. USA 1985, 82, 4379.